Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 9/30246% above fair value
$4.71+0.05 (+1.18%)
Close on Nov 13, 2026Market cap $65.49MP/E –Yield –
Champions Oncology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Champions Oncology's price to sales ratio was 1.1× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 1.0× to 2.8×, with a median of 1.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.1× | −0.5 |
| 2025 | Dec 31, 2025 | 1.6× | −0.5 |
| 2024 | Dec 31, 2024 | 2.2× | +0.7 |
| 2023 | Dec 29, 2023 | 1.5× | +0.4 |
| 2022 | Dec 30, 2022 | 1.1× | −1.4 |
| 2021 | Dec 31, 2021 | 2.5× | −1.3 |
| 2020 | Dec 31, 2020 | 3.9× | +0.5 |
| 2019 | Dec 31, 2019 | 3.4× | −0.5 |
| 2018 | Dec 31, 2018 | 3.9× | +1.5 |
| 2017 | Dec 29, 2017 | 2.4× | +0.4 |
| 2016 | Dec 30, 2016 | 2.1× | −0.8 |
| 2015 | Dec 31, 2015 | 2.9× | −0.5 |
| 2014 | Dec 31, 2014 | 3.4× | −0.9 |
| 2013 | Dec 31, 2013 | 4.2× | +2.8 |
| 2012 | Dec 31, 2012 | 1.4× | −1.9 |
| 2011 | Dec 30, 2011 | 3.3× | – |
See a number that looks wrong?